Aims: Using the Oslo Study of 1972-1973, we wished to compare the long-term mortality pattern up to 40 years, in both the healthy cardiovascular groups at supposedly high and low risk, and in some groups having cardiovascular disease at screening. Methods: At the screening, 16,203 (63% of those invited) men aged 40-49 years participated. Study groups were identified by means of questionnaires regarding diseases, blood pressure and measurements of total cholesterol, triglycerides and glucose. We identified six groups: very high cholesterol, very high blood pressure, very high glucose, non-smoking with non-elevated such risk factors, from a randomized diet and antismoking trial, and a randomized drug treatment in mildto-moderate hypertension. Statistical analyses were by Cox regression analysis, with Kaplan-Meier graphs. Results: The supposedly low-risk group had a total mortality of one-third of other groups, such as: men with hypertension, diabetes or hypercholesterolemia, or those whom participated in the two trials. Between these latter groups, we found 2-5 years of difference in their median survival time, but their absolute risk stayed at rather high levels through all the years, with the median remaining a lifetime that was 3-8 years shorter than the men whom were free of known cardiovascular disease, diabetes or hypertension. Conclusions: The long-term preventive effects on total mortality seem large, if the levels of the classical risk factors of blood pressure, total cholesterol and glucose can be adequately controlled, concurrently with a non-smoking behavior. The study indicated that non-smoking and a low total cholesterol value were the most important contributors to extended survival.
Introduction
, a cardiovascular study in Oslo, Norway took place that was the first in a series of similar studies performed by the National Health Service in different Norwegian counties [1] . Repeated screenings were performed through the years and the analyses of the collected data have provided much knowledge of cardiovascular disease (CVD) epidemiology in the Norwegian population [2] [3] [4] [5] [6] [7] [8] [9] .
Since World War II, myocardial infarction (MI) incidence and mortality had increased in all years and had reached epidemic proportions, so prevention strategies were highly needed. Among several purposes of the Oslo study screening was the recruitment of participants to two randomized controlled trials, among supposedly healthy men with a high risk of developing CVD. During the screening and two reexaminations to include men with no cardiovascular disease to the two trials, one diet and antismoking trial, and one drug trial regarding mild hypertension [10, 11] ; several other groups supposedly at both low and high risk were pre-specified. These were participants with hypertension and hypercholesterolemia with levels above those selected for the trials, newly detected diabetics and a non-smoking group with simultaneously lower levels of the classical risk factors. Since then, the levels of classical risk factors have been drastically reduced, current smoking prevalence has decreased to less than one-half the previous amount, more effective drug treatments for hypertension and hypercholesterolemia have been documented, as well as better treatments and procedures in secondary prevention. At the same time, large dietary changes took place, with more sedentary behavior and a massive increase in body mass index (BMI). The prognosis of the pre-specified groups from the Oslo Study would, therefore, be hard to predict. Some men had also experienced a cardiovascular event or had diabetes at the time of screening, and their survival has also remained unknown during these years. Thus, the purpose of this study was to report the long-term survival results in the pre-defined subgroups, as well as the diseased groups, during an almost 40-year time period. During 1972 During -1973 , all men who were born in Oslo in 1923-1932 were invited to a screening examination for CVD. There were 25,915 men eligible, and 16,203 participated (63 %). They filled in a questionnaire about prevalent CVD and diabetes. Men without such diseases, called healthy, had two reexaminations follow, to include the participants into planned randomized trials [3] . In the mild hypertension trial, men with blood pressure 150-179/95-109 mmHg were included; whereas men with total cholesterol at 6.4-8.9 mmol/l were included into the diet and antismoking trial, provided they have a coronary risk score in the upper quartile, in a risk score distribution based on the three classical risk factors: systolic blood pressure, total cholesterol and cigarette smoking [3].
Material and methods
An assumed low-risk group consisted of men with total cholesterol at screening (by the liebermann Burchart method) < 6.0 mmol/l with fasting given at the first re-examination, and with blood pressure < 145/95 mmHg, in both investigations. These men should not have smoked cigarettes nor be currently smoking a pipe nor cigar. Finally, their fasting triglycerides should be < 4.0 mmol/l and their fasting blood sugar < 9.5 mmol/l. The intention was to include 500 participants to this group, but it ended up with 367 men, due to a lower participation proportion than anticipated.
Men with a higher blood pressure than those included in the mild hypertension trial (placed in the high blood pressure group) were referred to specialized hypertension clinics, as were men with higher total cholesterol than those in the diet and antismoking trial (placed in the high cholesterol group).
The same took place for those with a fasting glucose > 9.5 mmol/l (newly detected diabetes). These two randomized trials were followed up with respect to morbidity and mortality of participants for a period up to 10 years, for a mild hypertension trial [12] ; and 20 years, if in the diet and antismoking trial [13] . Separate reports with the mortality results given by intervention/treatment group for up to 40 years are planned for publication. Thus, there are six assumed healthy groups to be compared, using one low-risk group and five groups that were assumed to be at a somewhat higher risk than the average screened population:
• The Mild Hypertension Trial;
• The Diet Anti-smoking Trial;
• The High Blood Pressure group;
• The High Cholesterol group; and • The Newly-Detected Diabetes group. This follow-up was extended to 31 December 2011, with respect to mortality. ICD code 410 was used for MI in version ICD8 and ICD9, and I21 in version ICD10. Statistics Norway added mortality data to the Oslo Study's data file, according to permissions given by the Data Inspectorate and tax authorities and the Department of Health; and the project was approved by the regional ethics committee for medical research.
Statistical methods
We used Cox proportional hazards regression models, and either time-to-death or time-to-death at first MI was the dependent variable in some analyses, and obtained age in others. Men who emigrated were censored at the date of emigration. The six risk group codes were exposure factors with the rest of men as reference, while adjustment factors were: total cholesterol, systolic blood pressure, glucose and daily smoking (Yes, No). The reference group consisted of all men except those in the six subgroups. They are a mixture of healthy and diseased men, whose risk level in itself is not of interest in this study.
When MI mortality was analyzed, all other causes of death were used as competing causes of death. The standard method used in STATA 13 was applied according to a method by Fine and gray [14] . A cumulative MI death incidence graph was also made by STATA 13, as were graphs of the hazard functions by time. The cumulative incidence gives an approximation to the MI mortality probabilities. In our case, with far more non-MI than MI deaths, the differences between competition-adjusted or non-adjusted results will probably be rather great.
To compare the predictive ability of risk factors on total mortality, log likelihood statistics were used. This contains all statistical information given in the model. A full model, with the six groups and the four classical risk factors, was estimated and its log likelihood was calculated. Then, one at a time, each of the four factors was removed from the model and it was rerun, obtaining an updated log likelihood: The change for each factor was recorded. The factor providing the greatest change would indicate the best predictive ability.
results Table I shows the number of deaths among men with MI, angina pectoris, hypertension and diabetes found at screening. In most categories, mortality risk was higher than in the healthy group, but some subjects may have had several categories of disease. The absolute risk of death or death at first MI were high in those whom had developed MI prior to screening, or whom had diabetes as compared to none. Figure 1 displays the unadjusted Kaplan Meier survival curves for the healthy men and for those with MI, diabetes, or drug-treated hypertension. All groups had markedly reduced median survival time, as compared to the healthy one, which had 35 years of median survival time after screening. Men with hypertension had 26 years of median survival, whereas diabetics and men with MI had only 19 years median survival.
The low-risk group experienced an especially low risk of death at first MI, with only eight such deaths through the 40 years of observation (Table II) . Also, their total mortality was low, as compared to the other risk groups or the healthy subgroup ( Figure 1 and Figure 2) . The low-risk group had a median survival time of 88 years and a total mortality of one third, as compared to other groups such as men with hypertension, diabetes, hypercholesterolemia or those whom participated in the two trials. Between these latter groups, we found 2-5 year differences in median survival time, but their absolute risk stayed at rather high levels through all the years; with their median remaining lifetime 3-8 years shorter than for men free of known cardiovascular disease, diabetes or hypertension.
Between the five pre-specified high-risk groups, there were only marginal total mortality risk differences, unadjusted for risk factors. This can also be seen from Figure 3 , where smoothed hazard rates are displayed by time, for each of the six risk groups. There is nothing to indicate that rates developed differently by time, since an exponential increase seemed to fit the data well in all groups. Table III shows hazard ratios for the six groups at risk, versus the reference adjusted for the four classical risk factors at the end of the table. Despite statistically significant differences in mortality to the reference group, differences were small between the six groups internally, as displayed in Supplementary  Figure 1 (supplementary material in online version). This indicates that the sole difference in mortality risk between the low-risk group and the five others was purely due to the measured differences in the four risk factor levels measured in [1972] [1973] . These factors associated strongly to 40-year mortality, when adjusted for each other. 
I. Holme
A cumulative incidence function graph was made for death at first MI ( Supplementary Figure 2 , found in the online version), showing the unadjusted different survival patterns between the low-risk and the other high-risk groups. In this curve, non-MI deaths are treated as competing risks. After about 20 years of follow-up, there seems to be a break in the development of MI mortality risk, but since the model uses only one underlying hazard function, these changes seem to happen at the same time, which is probably not fully true. It should rather be interpreted that a shift in the decline of MI mortality took place at some time during the 1990s. The poorest survival was in the newly-detected diabetes group. The low-risk group still had the best survival, but differences to the other groups were moderate yet still present. When adjustments were made for the four risk factors, there was no significant difference between any groups, as compared to the reference (data not shown).
The log likelihood analysis showed that smoking was by far the most predictive risk factor among the four classical ones. When smoking was removed from the full model, log likelihood was reduced by 621.7 units, whereas this reduction was 205.1 for systolic blood pressure, 83.8 for total cholesterol and 59.0 for glucose.
Discussion
This is the first report of the long-term prognosis of six pre-specified at-risk groups in the Oslo Study from [1972] [1973] . The study validates the importance in mortality of classical risk factors, measured at middle age through being elderly and at old age, despite drastic changes in risk factor distributions and treatment modalities introduced in Norway since that time.
There was a high excess mortality in the prevalent MI men in this study, with a relative risk of 3.3 (2.8-3.9), which is well known from previous studies among survivors from hospitalized acute MI patients [13] , but it is evidently also valid for patients with prevalent coronary heart disease. Due to the generally much better control of MI risk factors, as well as a lower absolute risk today, together with improved treatment strategies of both acute MI as well as secondary prevention by potent drugs such as statins, it is not clear whether such findings will be valid in the future. Men with diabetes also had a clearly excessive mortality as compared to healthy men, with hazard ratio (HR) = 2.9 (2.5-3.5), but treatment strategies have not resulted in substantial risk reductions [15] . After 30 years of follow-up, 23% were alive among the established diabetics; whereas this was 45% for the newly-detected ones. It could be that the latter group had had their diabetes for a shorter time, resulting in somewhat longer survival. The low-risk group had very few deaths at first MI. The concept of selecting non-smoking men without high levels of classical risk factors proved to give a low mortality risk both of MI and totally. The group results indicate the great prevention potential, even in total mortality, if levels of classical risk factors can be kept fairly low, while avoiding the habit of smoking. This happened despite the great changes in lifestyle, and advancements in treatment and intervention procedures, during these years. The main factor to combat is smoking, because that factor damages many organ systems and it showed up in the prognostic analyses to be a better predictor for total mortality than the others. Also, the other factors have been influential, since adjustments for them did close the gap between risk groups, with regard to survival.
In Norway, massive reductions in total cholesterol (about 1 mmol/l in Norway), a more effective and metabolically neutral hypertension control, and a more than 50% reduction in smoking prevalence have, together with more effective procedures and treatments of acute MI and better drugs in secondary prevention, more or less eliminated coronary heart disease mortality at younger ages and substantially reduced it in the elderly. This has, in all likelihood, resulted considerably in the impressive fact that the average lifetime has increased by 1 year for every 5 running years, during the latest 2-3 decades. conclusions large differences in long-term survival took place between groups in which the classical risk factor levels differed. Today these are, except for glucose, regarded as causal by most researchers; and the large reductions we have seen in cardiovascular and total mortality in the population as a whole during these 40 years are partly a result of the reduction in levels of these risk factors, mainly through lifestyle changes. At the same time modern drugs, such as metabolically-neutral antihypertensive drugs and statins, have been available to treat patients at high cardiovascular risk.
Judging from Table III and the observed large changes in smoking habits and total cholesterol in Norway, the greatest risk reductions are probably due to the massive reduction in smoking and the changes in total cholesterol. The large increase in BMI and diabetes in the population has, so far, not transferred into increased mortality at the population level; however, there are observations in Sweden and Finland that the cholesterol level is again increasing slightly, probably due to the big wave of protein-rich and fatty diets that are promoted by some to reduce BMI levels in the overweight and obese (16, 17) . If this trend becomes massive, it may announce a less beneficial development in CVD mortality trends in the years to come.
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